NCT04464460View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 25, 2020

Primary Completion Date

October 30, 2020

Study Completion Date

October 30, 2020

Conditions
Coronavirus Disease
Interventions
DRUG

TAK-671

TAK-671 intravenous infusion.

DRUG

TAK-671 Placebo

TAK-671 placebo-matching intravenous infusion.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY